13F Holdings
中文EN

LXRX LEXICON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1062822 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.6%
TTM net income YoY9.1%
TTM EPS YoY21.1%
Revenue 3-yr CAGR317.1%
Net income 3-yr CAGR—

Margins

Gross margin98.9%
Operating margin-147.4%
Net margin-161.8%
FCF margin—
EBITDA margin-146.3%

Returns

ROE-43.9%
ROA-27.8%
ROIC (approx.)-33.3%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets32.3%
Debt / equity0.32x
Current ratio10.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$49.80M$31.08M$1.20M$139,000$298,000
Cost of revenue$274,000$616,000$85,000$0$0
Gross profit$49.53M$30.46M$1.12M$139,000$298,000
R&D expense$61.12M$84.48M$58.89M$52.82M$55.05M
SG&A expense$37.32M$143.10M$113.98M$48.08M$32.34M
Operating income-$48.91M-$197.12M-$171.75M-$100.76M-$87.09M
Interest expense———$2.78M$802,000
Pretax income————-$87.76M
Income tax—$0$0$0$0
Net income-$50.34M-$200.40M-$177.12M-$101.94M-$87.76M
EBITDA-$48.29M-$196.58M-$171.20M-$100.33M-$86.80M
EPS (basic)-0.14-0.63-0.80-0.62-0.60
EPS (diluted)-0.14-0.63-0.80-0.62-0.60
Weighted avg. shares (diluted)363.05M320.03M221.13M165.73M145.65M
Balance sheet
Cash & equivalents$34.33M$66.66M$22.46M$46.34M$64.06M
Short-term investments$61.90M$171.30M$147.56M$92.01M$22.68M
Receivables$2.38M$3.47M$1.01M$28,000$14,000
Inventory$281,000$231,000$381,000$0—
Current assets$101.89M$246.19M$176.55M$140.87M$88.92M
PP&E, net$1.86M$2.48M$1.99M$2.07M$1.18M
Goodwill$44.54M$44.54M$44.54M$44.54M$44.54M
Total assets$184.99M$298.42M$229.43M$194.30M$136.91M
Current liabilities$20.87M$45.25M$31.55M$23.17M$22.12M
Short-term debt$4.59M$0——$0
Long-term debt$49.41M$100.30M$99.51M$48.58M$0
Total debt$54.00M$100.30M$99.51M$48.58M$0
Total liabilities$77.45M$152.47M$136.32M$77.17M$23.31M
Shareholders' equity$107.54M$145.95M$93.11M$117.12M$113.59M
Net debt$19.68M$33.64M$77.04M$2.23M-$64.06M
Shares outstanding365.85M363.02M———
Cash flow statement
Operating cash flow-$67.85M-$178.78M-$161.90M-$88.85M-$87.02M
Capital expenditure$0$1.03M$470,000$1.33M$1.22M
Free cash flow-$67.85M-$179.81M-$162.37M-$90.18M-$88.24M
Investing cash flow$113.02M-$15.38M-$49.94M-$71.08M$2.11M
Financing cash flow-$48.50M$238.35M$187.96M$142.21M$22.71M
Depreciation & amortization$621,000$534,000$554,000$427,000$292,000
Stock-based compensation$12.52M$13.50M$14.34M$11.52M$10.58M
Share buybacks—$1.73M$824,000$864,000$2.67M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.